日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers

PARP抑制剂奥拉帕尼和AKT抑制剂卡帕替尼治疗BRCA1/2突变型和非BRCA1/2突变型癌症患者的I期试验

Yap, Timothy A; Kristeleit, Rebecca; Michalarea, Vasiliki; Pettitt, Stephen J; Lim, Joline S J; Carreira, Suzanne; Roda, Desamparados; Miller, Rowan; Riisnaes, Ruth; Miranda, Susana; Figueiredo, Ines; Rodrigues, Daniel Nava; Ward, Sarah; Matthews, Ruth; Parmar, Mona; Turner, Alison; Tunariu, Nina; Chopra, Neha; Gevensleben, Heidrun; Turner, Nicholas C; Ruddle, Ruth; Raynaud, Florence I; Decordova, Shaun; Swales, Karen E; Finneran, Laura; Hall, Emma; Rugman, Paul; Lindemann, Justin P O; Foxley, Andrew; Lord, Christopher J; Banerji, Udai; Plummer, Ruth; Basu, Bristi; Lopez, Juanita S; Drew, Yvette; de Bono, Johann S

First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors

AT13148(一种双重 ROCK-AKT 抑制剂)在实体瘤患者中的首次人体研究

McLeod, Robert; Kumar, Rajiv; Papadatos-Pastos, Dionysis; Mateo, Joaquin; Brown, Jessica S; Garces, Alvaro H Ingles; Ruddle, Ruth; Decordova, Shaun; Jueliger, Simone; Ferraldeschi, Roberta; Maiques, Oscar; Sanz-Moreno, Victoria; Jones, Paul; Traub, Stephanie; Halbert, Gavin; Mellor, Sarah; Swales, Karen E; Raynaud, Florence I; Garrett, Michelle D; Banerji, Udai

Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma

胶质母细胞瘤的分子异质性和免疫抑制微环境

DeCordova, Syreeta; Shastri, Abhishek; Tsolaki, Anthony G; Yasmin, Hadida; Klein, Lukas; Singh, Shiv K; Kishore, Uday

Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation

多激酶抑制剂AT13148在细胞、小鼠和患者体内的代谢组学变化与NOS调控相关。

Pal, Akos; Asad, Yasmin; Ruddle, Ruth; Henley, Alan T; Swales, Karen; Decordova, Shaun; Eccles, Suzanne A; Collins, Ian; Garrett, Michelle D; De Bono, Johann; Banerji, Udai; Raynaud, Florence I

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

首次对晚期实体瘤患者进行 GSK2636771(一种磷酸肌醇 3 激酶 β 选择性抑制剂)的人体研究

Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, Howard A Burris, Sae-Won Han, Karen Swales, Shaun Decordova, M Phillip DeYoung, Deborah A Smith, Shanker Kalyana-Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M Tolson, Sun Young Rha, Hyun Cheol Chung, Joseph P Eder, Sunil Sharma, Yung-Jue

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

首次人体试验研究口服I类PI3K抑制剂CH5132799在转移性癌症患者中的毒性、药代动力学和药效学。

Blagden, Sarah; Omlin, Aurelius; Josephs, Debra; Stavraka, Chara; Zivi, Andrea; Pinato, David J; Anthoney, Alan; Decordova, Shaun; Swales, Karen; Riisnaes, Ruth; Pope, Lorna; Noguchi, Kohei; Shiokawa, Rie; Inatani, Michiyasu; Prince, Jenny; Jones, Keith; Twelves, Chris; Spicer, James; Banerji, Udai